Is cytisine contraindicated in smoking patients with coronary artery disease after percutaneous coronary intervention?

Ramotowski, Bogumił; Budaj, Andrzej

doi:10.33963/kp.a2021.0025

Cited by 4 publications

(4 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Seven newly conducted RCTs [15][16][17][18][19][20][21] were identified that were not considered in any of the preceding rereviews [2,23,24,27]. Eleven trials [28][29][30][31][32][33][34][35][36][37] were excluded. The excluded studies are briefly described, with justification for each exclusion, in the Characteristics of Excluded Studies tables (Supporting information).…”

Section: Agreements and Disagreements With Other Studies Or Reviewsmentioning

confidence: 99%

Evaluation of the effectiveness of cytisine for the treatment of smoking cessation: A systematic review and meta‐analysis

De Santi,

Orellana,

Di Niro

et al. 2023

Addiction

View full text Add to dashboard Cite

Background and aimsSmoking is considered the main cause of preventable death world‐wide. This study aimed to review the efficacy and safety of cytisine for smoking cessation.MethodsThis review included an exhaustive search of databases to identify randomized controlled trials (RCTs) in health centers of any level with smokers of any age or gender investigating the effects of cytisine at standard dosage versus placebo, varenicline or nicotine replacement therapy (NRT).ResultsWe identified 12 RCTs. Eight RCTs compared cytisine with placebo at the standard dose covering 5922 patients, 2996 of whom took cytisine, delivering a risk ratio (RR) of 2.25 [95% confidence interval (CI) = 1.42–3.56; I2 = 88%; moderate‐quality evidence]. The greater intensity of behavioral therapy was associated directly with the efficacy findings (moderate‐quality evidence). The confirmed efficacy of cytisine was not evidenced in trials conducted in low‐ and middle‐income countries. We estimate a number needed to treat (NNT) of 11. Two trials compared the efficacy of cytisine versus NRT, and the combination of both studies yields modest results in favor of cytisine. Three trials compared cytisine with varenicline, without a clear benefit for cytisine. Meta‐analyses of all non‐serious adverse events in the cytisine group versus placebo groups yielded a RR of 1.24 (95% CI = 1.11–1.39; participants = 5895; studies = 8; I2 = 0%; high‐quality evidence).ConclusionsCytisine increases the chances of successful smoking cessation by more than twofold compared with placebo and has a benign safety profile, with no evidence of serious safety concerns. Limited evidence suggests that cytisine may be more effective than nicotine replacement therapy, with modest cessation rates.

show abstract

Section: Agreements and Disagreements With Other Studies Or Reviewsmentioning

confidence: 99%

Evaluation of the effectiveness of cytisine for the treatment of smoking cessation: A systematic review and meta‐analysis

De Santi,

Orellana,

Di Niro

et al. 2023

Addiction

View full text Add to dashboard Cite

show abstract

“…Only 64 (26.5%) patients in the present study used any form of pharmacological smoking aid. We failed to find any correlation between drug use and effect in SC; but, as reported previously by our group, cytisine use may be effective only in patients who completed the treatment [28]. We did not measure e-cigarette usage which might be relevant in SC but also might carry harmful effects [29].…”

Section: Discussionmentioning

confidence: 63%

Smoking cessation after coronary angiography and percutaneous coronary intervention

Ramotowski¹,

Foryś²,

Dzida³

et al. 2022

Polish Archives of Internal Medicine

Self Cite

View full text Add to dashboard Cite

Smoking is a single major avoidable cause of premature deaths in Poland, but data on smoking cessation rates, effective support and factors related to smoking cessation are still inadequate. In the cohort of smoking patients after coronary angiography we found that prolonged and scheduled second hospitalization, low measured nicotine dependence, and a high load of pack-years are factors related to successful smoking cessation. These findings indicate the need of intensive in-hospital support and repetitive counseling for smoking cessation in this group of patients.

show abstract

“…La seguridad de TSN se ha comprobado en multitud de estudios 41 , 42 . Un estudio prospectivo, no aleatorizado, realizado en 117 fumadores sometidos a una intervención coronaria percutánea 30 días antes del tratamiento con citisina concluyó que la citisina no incrementa los efectos adversos en estos pacientes 43 . Por otro lado, Prochaska y Hilton 44 realizaron un metaanálisis de 22 ensayos clínicos, doble ciego, controlados con placebo, para valorar el riesgo de eventos adversos cardiovasculares en pacientes tratados con vareniclina durante el tratamiento y después de 30 días de finalizar el mismo, donde no se observó un aumento de eventos cardiovasculares.…”

Section: ¿Se Puede Hacer Una Intervención En Tabaquismo En Cualquier ...unclassified

Preguntas y respuestas en tabaquismo

Mavárez¹,

Villalona²,

Moreno³

et al. 2023

Open Respiratory Archives

View full text Add to dashboard Cite

Is cytisine contraindicated in smoking patients with coronary artery disease after percutaneous coronary intervention?

Cited by 4 publications

References 23 publications

Evaluation of the effectiveness of cytisine for the treatment of smoking cessation: A systematic review and meta‐analysis

Evaluation of the effectiveness of cytisine for the treatment of smoking cessation: A systematic review and meta‐analysis

Smoking cessation after coronary angiography and percutaneous coronary intervention

Preguntas y respuestas en tabaquismo

Contact Info

Product

Resources

About